TY  - JOUR
AU  - Arbour, Kathryn C
AU  - Mezquita, Laura
AU  - Long, Niamh
AU  - Rizvi, Hira
AU  - Auclin, Edouard
AU  - Ni, Andy
AU  - Martínez-Bernal, Gala
AU  - Ferrara, Roberto
AU  - Lai, W Victoria
AU  - Hendriks, Lizza E L
AU  - Sabari, Joshua K
AU  - Caramella, Caroline
AU  - Plodkowski, Andrew J
AU  - Halpenny, Darragh
AU  - Chaft, Jamie E
AU  - Planchard, David
AU  - Riely, Gregory J
AU  - Besse, Benjamin
AU  - Hellmann, Matthew D
PY  - 2018
DO  - 10.1200/JCO.2018.79.0006
UR  - http://hdl.handle.net/10668/12856
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade. On-treatment...
LA  - en
KW  - Adrenal Cortex Hormones
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents, Immunological
KW  - B7-H1 Antigen
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Drug Interactions
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Programmed Cell Death 1 Receptor
KW  - Treatment Outcome
TI  - Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 36
ER  -